Study on the Correlation between the Detection of Tumor Markers in Abdominal Effusion and Chemotherapy Sensitivity

Martin Gummert, Namshin Kim


Since most patients with ovarian cancer are in the advanced stage when they are prone to recurrence, it is difficult to detect and treat ovarian cancer. There are tumor serum markers in the ascites. Therefore, the study explored the correlation between the serum marker levels of the ascites and chemotherapy sensitivity in patients with ovarian malignant tumors. First, 50 patients with nested cancer were selected as research subjects and received treatment, and then immediately 200 mg carboplatin + 100 mL normal saline was placed in the abdominal cavity of all patients, which was equivalent to an intraperitoneal chemotherapy. Carboplatin + docetaxel combined with intravenous chemotherapy was started 3 weeks after surgery, and chemotherapy was given every 3 weeks for a total of 5 to 6 courses. The serum levels of CA125, CA199, CEA and AFP in peripheral blood and peripheral blood were determined by ELISA. The results showed that the levels of CA125, CA199, CEA and AFP in serum and ascites after chemotherapy were lower than before chemotherapy (P<0.05). The short-term effective rate of 50 ovarian cancer patients (8 CR, 28 PR, 12 SD, 2 PD) was 72.00 %. Therefore, patients with ovarian malignant tumors had a good short-term curative effect after chemotherapy, which can reduce the ascites and serum levels of CA125, CA199, CEA, AFP for clinical reference value.


chemotherapy sensitivity; tumor markers; malignant ovarian cancer

Full Text:



Burgetova A,Matejovsky Z,Zikan M,et al. The association of enchondromatosis with malignant transformed chondrosar- coma and ovarian juvenile granulosa cell tumor( Ollier dis- ease)〔J〕. Taiwan J Obstet Gynecol,2017,56 ( 2) : 253- 257.

Czekierdowska S,Stachowicz N,Chróζciel M,et al. Prolifer- ation and maturation of intratumoral blood vessels in women with malignant ovarian tumors assessed with cancer stem cells marker nestin and platelet derived growth factor P D G F - B.〔J〕. Gine kologia Polska,2017,88(3): 120 .

Gershenson DM,Frazier AL. Conundrums in the managem- ent of malignant ovarian germ cell tumors: Toward acute morbidity and late effects of treatment〔J〕. Gynecol Oncol,2016,143( 2) : 428-432.

Sears S,Singh S,Shojaei H,et al. High-dose chemotherapy and stem-cell rescue for salvage therapy for relapsed malig- nant mixed ovarian germ cell tumor: A case report〔J〕. Gy- necol Oncol Rep,2017,22( 3) : 72-74.

Hanna TP,Delaney GP,Barton MB. The Population Benefit of Radiotherapy for Malignant Brain Tumors: Local Control and Survival Estimates for Guideline-Based Use〔J〕. J Natl Compr Canc Netw,2016,14( 9) : 1111-1119. .

Zhang L, Li J, Xia Q, et al. Application of combined detection of tumor markers in the diagnosis of ovarian malignant tumors〔J〕. Zhong Guo Wei Sheng Jian Yan Zai Zhi, 2018,12( 7) : 824-826.

Guo J,Zhao H, Miao Rui, et al. The clinical application of color Doppler ultrasound combined with detection of different types of tumor markers in the early diagnosis of ovarian cancer〔J〕.He Bei Yi Yao, 2018,40( 8) : 25-28.

Park JY,Kim DY,Suh DS,et al. Analysis of outcomes and prognostic factors after fertility-sparing surgery in malignant ovarian germ cell tumors.〔J〕. Gynecol Oncol,2017,145 ( 3) : 513.

Kondo T,Kitayama H,Sugiyama J,et al. Conversion therapy of gastric cancer with massive malignant ascites and ovarian metastases by systemic and intraperitoneal chemotherapy [J]. Mol Clin Oncol,2016,5( 6) : 740-744.

Vega JFS,González AMP,Astudillo JAC,et al. Predictive e- quation of metastasis in patients with malignant ovarian epi- thelial tumors with the Ca-125 marker〔J〕. Bmc Cancer, 2018,18( 1) : 587.

Pascual A,Guerriero S,Rams N,et al. Clinical and ultra- sound features of benign,borderline,and malignant invasive mucinous ovarian tumors.〔J〕. Eur J Gynaecol Oncol, 2017,38( 3) : 382-386.

Mesbah Ardakani N,Giardina T,Amanuel B,et al. Molecu- lar Profiling Reveals a Clonal Relationship Between Ovarian Mucinous Tumors and Corresponding Mural Carcinomatous Nodules〔J〕. Am J Surg Pathol,2017,41( 9) : 1261.

Jiang ZH,Li KT,Tian JW,et al. An overview of the devel- opment and application of the sonographic scoring system: differentiation of malignant from benign ovarian tumors〔J〕. Mol Clin Oncol,2016,5( 6) : 740-744.

Hu X, Zhou J, Hong Y, The clinical value of color Doppler ultrasound combined with tumor markers CA125 and CA199 in the diagnosis of early epithelial ovarian cancer〔J〕.Zhong Guo Fu You Bao Jian, 2018,12( 8) : 1848-1851.

Liu Y, Shou H, CA199、CA125 The value of combined detection in the identification and condition judgment of ovarian masses〔J〕. Zhong Guo Fu You Bao Jian,2018,33 ( 1 ) : 6 4 -6 6 .

Wang Q, Zhao X, Guo P,et al. The clinical value of ultrasound combined with CA125 and CA199 in the identification of ovarian tumors〔J〕. Xi Bu Yi Xue, 2017,29( 9) : 1221-1224.

Fan C , Xiao G, Xu G,et al. The application value of tumor markers HE4, CA125, CA199, CA153, AFP in the early diagnosis of ovarian cancer〔J〕Guo Ji Jian Yan Yi Xue Za Zhi, 2017,38( 19) : 2718-2719.

Zheng F, Jin G, Liu Y, et al. The value of combined detection of carbohydrate antigen 199, carcinoembryonic antigen and alpha-fetoprotein in the diagnosis of ovarian cancer〔J〕.Han Nan Yi Xue, 2018,12( 1) : 74-76.

Qu M, Deng X, Zhao K, et al. The clinical value of combined detection of serum CA125, CEA and AFP in the diagnosis of ovarian malignant tumors〔J〕. Shi Yong Ai Zheng Zai Zhi, 2017,32( 7) : 1065-1068.

Gong S, Chen Y, Zhang Y, et al. The value of serum CA125, HE4 and Copenhagen index in the differential diagnosis of benign and malignant ovarian epithelial tumors〔J〕.Nan Fang Yi Ke Da Xue Xue Bao,2017,37( 5) : 66-70.

Dong D, Gu J, Zhao S, et al. The value of serum HE4, CA125 detection and ROMA model in the diagnosis of ovarian cancer〔J〕.Chong Qing Yi Xue, 2017,46( 5) : 7-9.



  • There are currently no refbacks.

Copyright (c) 2020 Martin Gummert, Namshin Kim

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.